Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies

Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yutani, Shigeru, Shirahama, Takahisa, Muroya, Daisuke, Matsueda, Satoko, Yamaguchi, Rin, Morita, Michi, Shichijo, Shigeki, Yamada, Akira, Sasada, Tetsuro, Itoh, Kyogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581512/
https://www.ncbi.nlm.nih.gov/pubmed/28622427
http://dx.doi.org/10.1111/cas.13301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581512/
https://www.ncbi.nlm.nih.gov/pubmed/28622427
http://dx.doi.org/10.1111/cas.13301

Ejemplares similares